GNH USA

Europe — EMA

Milrinone Pinewood Laboratories

GNH USA supplies Milrinone (Milrinone), a phosphodiesterase‑3 inhibitor for acute decompensated heart failure and cardiogenic shock. Request a quote today.

Milrinone

Request sourcing

1
Pack/s

What is Milrinone?

Milrinone, the active ingredient in Milrinone Pinewood Laboratories, is a phosphodiesterase 3 inhibitor presented as an intravenous solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Milrinone Pinewood Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Milrinone used for?

Milrinone acts as an inotropic and vasodilator agent for severe cardiac conditions.

Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion. Low cardiac output syndrome after cardiac surgery: enhances myocardial contractility to stabilize hemodynamics.

What are the side effects of Milrinone?

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially with rapid infusion. - Headache: mild to moderate intensity. - Arrhythmias: premature beats or tachyarrhythmias. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring intervention. - Ventricular arrhythmias: life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Thrombocytopenia: low platelet count. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice.

What precautions apply to Milrinone?

Milrinone requires careful monitoring and specific handling precautions.

Monitor blood pressure: watch for hypotension during and after infusion. Observe cardiac rhythm: detect arrhythmias promptly. Adjust dose in renal impairment: reduce dosage if creatinine clearance is decreased. Use cautiously after recent myocardial infarction: risk of ischemia may be higher. Avoid in uncontrolled arrhythmias: may exacerbate rhythm disorders. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Milrinone interact with?

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Concurrent potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase milrinone plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response. - Diuretics: can potentiate hypotensive effects. - Anticoagulants: may raise bleeding risk. - Digoxin: combined use can increase arrhythmia risk. - Calcium channel blockers: may affect hemodynamic stability.

Frequently asked questions

What conditions is Milrinone used to treat?+
Milrinone is used in hospital settings for acute decompensated heart failure and cardiogenic shock, where rapid improvement of cardiac output and reduction of vascular resistance are needed. It may also be employed for low‑output states after cardiac surgery to support myocardial contractility.
How does Milrinone work in the body?+
Milrinone blocks the enzyme phosphodiesterase‑3, which normally degrades cyclic AMP. By preserving cAMP levels in heart muscle and vascular smooth muscle, it enhances calcium‑mediated contraction (positive inotropy) and promotes vasodilation, together improving blood flow and cardiac performance.
What is the usual dose of Milrinone?+
The dose of Milrinone is individualized by the prescribing clinician based on the patient’s weight, renal function, and hemodynamic status. A typical regimen involves a loading dose followed by a continuous intravenous infusion, but exact parameters are set by the treating physician.
Is Milrinone safe during pregnancy or breastfeeding?+
The safety of Milrinone in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a specialist is essential.
How do I order Milrinone from GNH USA?+
To request Milrinone, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.
How does Milrinone compare with other inotropic agents?+
Milrinone differs from catecholamine inotropes such as dopamine or dobutamine by acting via phosphodiesterase‑3 inhibition rather than adrenergic receptors. This mechanism provides both inotropic support and vasodilation, which can reduce afterload, whereas catecholamines primarily increase heart rate and may raise systemic vascular resistance.
What are the recommended storage conditions for Milrinone?+
Milrinone intravenous solution should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the container. If the product reaches room temperature, use it promptly according to the manufacturer’s guidance.
How is Milrinone administered to patients?+
Milrinone is given exclusively by intravenous infusion. After a possible loading dose, a continuous infusion is maintained using an infusion pump, allowing precise control of the rate. Administration is performed by trained healthcare professionals in a monitored setting such as an intensive care unit.
What are the most serious risks associated with Milrinone therapy?+
The most serious risks include severe hypotension, life‑threatening ventricular arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Continuous hemodynamic monitoring is essential to detect these events early and intervene appropriately.
Who should not receive Milrinone?+
Milrinone is contraindicated in patients with uncontrolled ventricular arrhythmias, severe aortic or mitral valve stenosis, or those who have had a recent myocardial infarction with ongoing ischemia. It should also be avoided in individuals with known hypersensitivity to milrinone or any component of the formulation.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Milrinone
Route
Intravenous Use
Manufacturer
Pinewood Laboratories Limited
Origin
EU

Related products

Asicor

Asicor

Milrinone

Pharmaselect International Beteiligungs Gmbh
EU
Asicor

Asicor

Milrinone

Pharmaselect International Beteiligungs Gmbh
EU
Asicord

Asicord

Milrinone

Pharmaselect International Beteiligungs Gmbh
EU
Asicord

Asicord

Milrinone

Pharmaselect International Beteiligungs Gmbh
EU